title: Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting.
abstract: BACKGROUND
  Knowledge on the efficacy and safety of adalimumab in psoriasis patients switching from etanercept is scarce, especially on the influence that causes of etanercept discontinuation may have on adalimumab response.
  
  
  OBJECTIVE
  To evaluate the response, adverse effects and factors that may influence the efficacy and safety of adalimumab in psoriasis patients who failed on etanercept therapy in a real-world setting.
  
  
  METHODS
  Data from all moderate to severe plaque psoriasis patients who switched from etanercept to adalimumab were extracted from a registry of biological therapies of our department. Primary endpoint was the percentage of patients achieving PASI 50 at weeks 12, 24, and 52. Secondary endpoints were the percentages of patients achieving PASI 75 and PASI 90, patients who maintained PASI values <5 and <3, and the safety of adalimumab.
  
  
  RESULTS
  Of 35 patients who fulfilled the study criteria, 82.9% achieved PASI 50 at week 12, 74.3% at week 24, and 74.3% at week 52 on adalimumab treatment. Eleven of 16 primary and 11 of 17 secondary nonresponders to etanercept responded to adalimumab. There were no treatment discontinuations due to side effects.
  
  
  CONCLUSIONS
  Previous etanercept failure seems not influence the success and safety of adalimumab treatment in moderate to severe plaque psoriasis.
authors.affiliation: Department of Dermatology and.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Fonseca
authors.forename: Raquel
authors.initials: R
authors.lastname: Iglesias
authors.forename: Sabela
authors.initials: S
authors.lastname: Paradela
authors.forename: Rosa M
authors.initials: RM
authors.lastname: Fernández-Torres
authors.forename: Laida
authors.initials: L
authors.lastname: Elberdín
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D001691:Biological Therapy / Q000379:methods; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: D000068879:Adalimumab; D000068800:Etanercept
keywords: Adalimumab; anti-tumor necrosis factor-alpha; biologic therapy; etanercept; psoriasis